# Ranolazine

Drug · id `cardio:ranolazine` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

Ranolazine is an antianginal, a medicine taken by mouth to treat angina. The US label read, for generic ranolazine extended-release tablets, lists the treatment of chronic angina and says the tablets may be used with several other medicine groups for the heart and blood vessels. The label says the mechanism of its antianginal effects has not been determined.

## Technical summary

RxNorm ingredient 35829; UNII A6IEZ5M406. MeSH descriptor D000069458 is Ranolazine. RxClass lists the FDA established pharmacologic class Anti-anginal; the atlas has no page for that class, so the record has no class parent. The label read is the Glenmark Pharmaceuticals Inc., USA generic extended-release tablet label, application ANDA211082, effective 2026-01-23 in openFDA. The plan row listed set id 00979fb3 (Viona Pharmaceuticals Inc, ANDA210188) beside the application number ANDA211082; the Glenmark label for ANDA211082 is used. An openFDA brand-name search for Ranexa returned no record on 2026-11-18, and the Aspruzyo Sprinkle record (NDA216018) and other generic and repackager labels were not read. This page records the label indication, the list of medicines the label says it may be used with, and the mechanism sentences only: no trial result and no dose is given.

## Claims, with the population each applies to

## Context: People with chronic angina, as described in the US label of generic ranolazine extended-release tablets

Recipient: Recipient not specified; Population: Patients with chronic angina, as the indications section of the label states. The label passages read do not state an age range.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Not stated in the label passages read; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)

### The US label of ranolazine extended-release tablets (Glenmark Pharmaceuticals Inc., USA, application ANDA211082; the version dated 2026-01-23 in openFDA) lists the treatment of chronic angina and says the tablets may be used with beta-blockers, nitrates, calcium channel blockers, anti-platelet therapy, lipid-lowering therapy, ACE inhibitors, and angiotensin receptor blockers. The label also says the mechanism of ranolazine's antianginal effects has not been determined. It says ranolazine can inhibit the cardiac late sodium current at therapeutic levels, and that the relationship of this inhibition to angina symptoms is uncertain.

- Category: Description
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Recipient not specified; Population: Patients with chronic angina, as the indications section of the label states. The label passages read do not state an age range.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Not stated in the label passages read; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)
- Limitations: This claim records what one US label says the medicine is indicated for and how it describes the medicine. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label is for a generic product; the brand label and other ranolazine products were not read. The list of medicines that may be used with it is the label's own statement and is not a recommendation of this atlas. The label passages read state no age range except where the claim says adults. Contraindications, warnings, interactions, use in pregnancy and in children, and dosing were not recorded. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked: 2026-11-18
- Sources:
  1. Background: openFDA drug label record for ranolazine extended-release tablets, Glenmark Pharmaceuticals Inc., USA label: indication, mechanism (Regulator, edition The openFDA drug label record for set id 0cf58732-c242-49b0-8e3f-248778b4458d (manufacturer Glenmark Pharmaceuticals Inc., USA, application ANDA211082), returned on 2026-11-18. The label text is dated 2026-01-23 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%220cf58732-c242-49b0-8e3f-248778b4458d%22&limit=1>
     Locator: results\[0\].openfda.application\_number\[0\]. Retrieved 2026-11-18T21:59:09Z. Source state: Current. Version fingerprint: b4f132e1c3f78d1f5437ed9faf41612ec62a96e7a270aeeefe960cb96fd683fb.
     How it applies: Application number of the label read.
  2. Background: openFDA drug label record for ranolazine extended-release tablets, Glenmark Pharmaceuticals Inc., USA label: indication, mechanism (Regulator, edition The openFDA drug label record for set id 0cf58732-c242-49b0-8e3f-248778b4458d (manufacturer Glenmark Pharmaceuticals Inc., USA, application ANDA211082), returned on 2026-11-18. The label text is dated 2026-01-23 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%220cf58732-c242-49b0-8e3f-248778b4458d%22&limit=1>
     Locator: results\[0\].effective\_time. Retrieved 2026-11-18T21:59:09Z. Source state: Current. Version fingerprint: b4f132e1c3f78d1f5437ed9faf41612ec62a96e7a270aeeefe960cb96fd683fb.
     How it applies: Effective date of the label text read.
  3. Supports: openFDA drug label record for ranolazine extended-release tablets, Glenmark Pharmaceuticals Inc., USA label: indication, mechanism (Regulator, edition The openFDA drug label record for set id 0cf58732-c242-49b0-8e3f-248778b4458d (manufacturer Glenmark Pharmaceuticals Inc., USA, application ANDA211082), returned on 2026-11-18. The label text is dated 2026-01-23 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%220cf58732-c242-49b0-8e3f-248778b4458d%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\]. Retrieved 2026-11-18T21:59:09Z. Source state: Current. Version fingerprint: b4f132e1c3f78d1f5437ed9faf41612ec62a96e7a270aeeefe960cb96fd683fb.
     How it applies: Label passage quoted in the research quote table (RAN-LB-04, RAN-LB-05).
  4. Supports: openFDA drug label record for ranolazine extended-release tablets, Glenmark Pharmaceuticals Inc., USA label: indication, mechanism (Regulator, edition The openFDA drug label record for set id 0cf58732-c242-49b0-8e3f-248778b4458d (manufacturer Glenmark Pharmaceuticals Inc., USA, application ANDA211082), returned on 2026-11-18. The label text is dated 2026-01-23 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%220cf58732-c242-49b0-8e3f-248778b4458d%22&limit=1>
     Locator: results\[0\].mechanism\_of\_action\[0\]. Retrieved 2026-11-18T21:59:09Z. Source state: Current. Version fingerprint: b4f132e1c3f78d1f5437ed9faf41612ec62a96e7a270aeeefe960cb96fd683fb.
     How it applies: Label passage quoted in the research quote table (RAN-LB-06, RAN-LB-07, RAN-LB-08).

## Connected pages

- FDA label lists the treatment of chronic angina as the indication: Angina pectoris (`cardio:angina-pectoris`) [a claim, not a settled fact; see claim `cardio:claim-fda-ranolazine-label-indications` and its context]
- The label says ranolazine extended-release tablets may be used with beta-blockers: Beta-blockers (drug class) (`cardio:beta-blockers`)
- The label says ranolazine extended-release tablets may be used with nitrates: Nitrates (`cardio:nitrates`)
- The label says ranolazine extended-release tablets may be used with calcium channel blockers: Calcium channel blockers (`cardio:calcium-channel-blockers`)
- The label says ranolazine extended-release tablets may be used with ACE inhibitors: ACE inhibitors (`cardio:ace-inhibitors`)
- The label says ranolazine extended-release tablets may be used with angiotensin receptor blockers: Angiotensin receptor blockers (ARBs) (`cardio:angiotensin-receptor-blockers-arbs`)
- The label says ranolazine extended-release tablets may be used with anti-platelet therapy: Antiplatelet drugs (`cardio:antiplatelet-drugs`)
- Files under this front: Medicines (`cardio:front-medicines`)

## Provenance

Content hash: 843798e30d762b96231c9045842b3ed4805308815ee63230a29310fa0807a291
Last substantive edit: 2026-11-18
Evidence last checked: 2026-11-18
